Page 11 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covaxin Phase 3 Trial Result: 65 2% Efficacy Against Delta Variant, 77 8% Against Symptomatic COVID-19 Infection

Covaxin Phase 3 Trial Result: 65.2% Efficacy Against Delta Variant, 77.8% Against Symptomatic COVID-19 Infection Covaxin, India s indigenous COVID-19 vaccine, has concluded its final phase 3 trials and the results are out. Read on to know all about it. Written by Jahnavi Sarma | Published : July 3, 2021 12:19 PM IST Bharat Biotech has announced the safety and efficacy analysis data from Phase 3 clinical trials of Covaxin, its whole virion inactivated vaccine against SARS-CoV2, developed in partnership with ICMR and NIV Pune. According to the trial result, Covaxin is well tolerated and the Data Safety Monitoring Board has not reported any safety concerns related to the it. Adverse reaction to this vaccine was lower than that seen in other COVID-19 vaccines. Interestingly, Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission. It must be noted here that no other licensed COVID-19 vac

Priya abrahamNational institute of virologyCovaxin phaseEfficacy against delta variantAgainst symptomaticData safety monitoring boardDirector national instituteBharat biotechUse listingதேசிய நிறுவனம் ஆஃப் வைராலஜிதகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகைஇயக்குனர் தேசிய நிறுவனம்பாரத் பயோடெக்பயன்பாடு பட்டியல்

Bharat Biotech Concludes Final Analysis for COVAXIN® Efficacy from Phase 3 Clinical Trials

Bharat Biotech Concludes Final Analysis for COVAXIN® Efficacy from Phase 3 Clinical Trials
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

Andhra pradeshUnited statesPriya abrahamKrishna ellaSuchitra ellaBalram bhargavaNational institute of virologyIndian council of medical researchNational institutes of health united statesAdjudication committeeDepartment of health researchBharat biotechNational institutesHealth unitedData safety monitoring boardManaging director

COVAXIN Has An Efficacy Of 78 8% Against COVID-19, Offers 62 5% Protection Against Delta Strain

COVAXIN Has An Efficacy Of 78 8% Against COVID-19, Offers 62 5% Protection Against Delta Strain
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Andhra pradeshKrishna ellaBalram bhargavaHyderabad based bharat biotechBharat biotechData safety monitoring boardManaging directorஆந்திரா பிரதேஷ்கிருஷ்ணா எல்லாபால்ராம் பார்கவாஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்பாரத் பயோடெக்தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகைநிர்வகித்தல் இயக்குனர்

Zydus Cadila seeks DCGI s Emergency Use Authorization for ZyCoV-D

Zydus Cadila today announced that the company has applied for Emergency Use Authorization (EUA) to the office of Drug Controller General of India (DCGI) for ZyCoV-D - its Plasmid DNA Vaccine against COVID-19. The company conducted the largest clinical trial for its COVID-19 vaccine in India so far in over 50 centers. This was also the first time that any COVID-19 vaccine has been tested in adolescent population in the 12-18 years age group in India. Around 1000 subjects were enrolled in this age group and the vaccine was found to be safe and very well tolerated. The tolerability profile was similar to that seen in the adult population. Primary efficacy of 66.6% has been attained for symptomatic RT-PCR positive cases in the interim analysis.

Zydus cadilaNational biopharma missionNational institute of virologyIndian council of medical researchDepartment of biotechnologyEmergency use authorizationDrug controller generalData safety monitoring boardNational instituteIndian councilMedical researchCapital marketஜய்துச் காடிலாதேசிய நிறுவனம் ஆஃப் வைராலஜிஇந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிதுறை ஆஃப் உயிரி தொழில்நுட்பவியல்

Zydus Cadila seeks emergency use nod for its COVID-19 vaccine for 12+ age

Zydus Cadila seeks emergency use nod for its COVID-19 vaccine for 12+ age BusinessToday.In © Provided by Business Today Zydus Cadila seeks emergency use nod for its COVID-19 vaccine for 12+ age Indian drugmaker Zydus Cadila announced on Thursday that it has applied for Emergency Use Authorisation (EUA) to the country s regulator for ZyCoV-D- its COVID-19 vaccine for those aged 12 years and above. The company has concluded its third phase trial. Zydus Cadila added that it plans to produce up to 120 million doses of the jab annually. The drugmaker has carried out the largest clinical trials for its Plasmid DNA vaccine against coronavirus in India so far in more than 50 centres.

Zydus cadilaSerum institute of india covishieldRussia gamaleya instituteBusiness today zydus cadilaEmergency use authorisationData safety monitoring boardSerum instituteBharat biotechஜய்துச் காடிலாதகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகைசீரம் நிறுவனம்பாரத் பயோடெக்